


This listing of claims will replace all prior versions, and listings of claims in the application:

1 **Claim 1.** (Previously presented) A compound having the formula:



4 R^1 , R^2 , R^3 and R^4 are members independently selected from H, substituted or
5 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or
6 unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or
7 unsubstituted heteroaryl, OR^8 , NO_2 , CN and halogen

9 R⁸ is a member selected from H, substituted or unsubstituted alkyl,
10 substituted or unsubstituted cycloalkyl and substituted or
11 unsubstituted aryl;

6 wherein

7 **R⁹** is a member selected from H, substituted or unsubstituted alkyl,
8 substituted or unsubstituted cycloalkyl, substituted or unsubstituted
9 heteroalkyl, NR¹⁰R¹¹ and OR¹¹

Page 2 of 9


21 R^{10} is a member selected from H, substituted or unsubstituted
22 alkyl, substituted or unsubstituted cycloalkyl and OR^{12}
23 wherein
24 R^{12} is a member selected from H, substituted or
25 unsubstituted alkyl, substituted or unsubstituted
26 cycloalkyl and substituted or unsubstituted
27 heteroalkyl;
28 R^{11} is a member selected from H, $C(O)R^{13}$, substituted or
29 unsubstituted alkyl, substituted or unsubstituted cycloalkyl,
30 substituted or unsubstituted heteroalkyl, substituted or
31 unsubstituted heterocycloalkyl, and substituted or
32 unsubstituted aryl, and wherein R^{10} and R^{11} , together with
33 the nitrogen to which they are bound, are optionally joined
34 to form a substituted or unsubstituted heterocycloalkyl ring
35 system having from 3 to 7 members
36 wherein
37 R^{13} is a member selected from H, substituted or
38 unsubstituted alkyl, substituted or unsubstituted
39 cycloalkyl, substituted or unsubstituted heteroalkyl
40 and $NR^{14}R^{15}$
41 wherein
42 R^{14} and R^{15} are members independently selected
43 from H, substituted or unsubstituted alkyl
44 and substituted or unsubstituted heteroalkyl;
45 R^6 is a member selected from substituted alkyl, substituted and unsubstituted
46 heteroalkyl, CN, substituted or unsubstituted aryl, substituted or
47 unsubstituted heteroaryl and $C(O)R^{16}$
48 wherein
49 R^{16} is a member selected from substituted or unsubstituted alkyl,
50 substituted or unsubstituted heteroalkyl, substituted or

51 unsubstituted aryl, substituted or unsubstituted heteroaryl, $\text{NR}^{17}\text{R}^{18}$
52 and OR^{17}
53 wherein
54 R^{17} and R^{18} are members independently selected from H,
55 substituted or unsubstituted alkyl, substituted or
56 unsubstituted heteroalkyl and substituted or unsubstituted
57 aryl, and wherein R^{10} and R^{11} , together with the nitrogen to
58 which they are bound, are optionally joined to form a
59 heterocycloalkyl ring system having from 3 to 7 members;
60 R^7 is a member selected from H, substituted or unsubstituted alkyl and substituted
61 or unsubstituted heteroalkyl.

1 **Claim 2.** (Previously presented) The compound according to claim 1, wherein at
2 least one of R^{10} and R^{11} is substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl.

1 **Claim 3.** (Previously presented) The compound according to claim 1, wherein R^5 is
2 a member selected from substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, substituted or
3 unsubstituted $\text{C}_1\text{-C}_6$ heteroalkyl, substituted or unsubstituted $\text{C}_1\text{-C}_6$ cycloalkyl and
4 substituted or unsubstituted $\text{C}_1\text{-C}_6$ heterocycloalkyl.

1 **Claim 4.** (Previously presented) The compound according to claim 1, having the
2 formula:



1 **Claim 5.** (Cancelled)

1 **Claim 6.** (Previously presented) The compound according to claim 4, wherein R^5 is
2 selected from substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl and substituted or unsubstituted
3 $\text{C}_1\text{-C}_6$ cycloalkyl.

1 **Claim 7.** (Previously presented) The compound according to claim 4, wherein R³ is
2 halogen.

1 **Claim 8.** (Previously presented) A pharmaceutical formulation comprising a
2 compound according to claim 1 and a pharmaceutically acceptable carrier.

1 **Claim 9.** (Withdrawn) A method of inhibiting HIV in a cell, said method
2 comprising contacting said cell with an amount of a compound according to claim 1
3 sufficient to inhibit said HIV.

1 **Claim 10.** (Withdrawn) The method according to claim 9, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 11.** (Withdrawn) A method of inhibiting reverse transcriptase in a cell, said
2 method comprising contacting said cell with an amount of a compound according to
3 claim 1 sufficient to inhibit said reverse transcriptase.

1 **Claim 12.** (Withdrawn) The method according to claim 9, wherein said cell is in a
2 human.

1 **Claim 13.** (Withdrawn) The method according to claim 10, wherein said cell is in a
2 human.

1 **Claim 14.** (Withdrawn) A method of treating HIV infection in a human subject
2 comprising administering to said subject an amount of a compound according to claim 1,
3 sufficient to treat said HIV infection.

1 **Claim 15.** (Withdrawn) The method according to claim 14, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 16.** (Withdrawn) A method of providing prophylaxis against HIV infection
2 comprising administering a prophylactic amount of a compound according to claim 1 to a
3 person who is at risk of HIV infection.

1 **Claim 17.** (Withdrawn) The method according to claim **13**, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 18.** (Previously presented) The compound according to claim **1**, wherein R⁶ is
2 a member selected from substituted and unsubstituted ether, substituted and unsubstituted
3 polyether, -CH₂OH, and -CH₂OC(O)CH₃.